Albuterol/budesonide significantly reduced the risk of severe asthma exacerbations vs albuterol alone in mild asthma based on BATURA results.

BATURA builds upon the previous Phase III MANDALA and DENALI trials and in totality, the clinical program demonstrates the benefit of as-needed AIRSUPRA in reducing the risk of severe exacerbations ...

AZ showed that use of inhaler Airsupra in those with mild asthma reduced the risk of severe exacerbations by 47% compared to albuterol.

As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to ...

Childhood asthma with recurrent exacerbations is more common in under-resourced areas, especially in minoritized children with parental asthma.

Connect Biopharma initiates Phase 2 Seabreeze STAT Asthma study, expects topline data in early 2026, assessing rademikibart's efficacy.

Respiratory infections represent the most common asthma exacerbation trigger, yet many patients lack clear protocols for adjusting management during these high-risk periods.

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy ...

Mice were protected against asthma exacerbations for weeks after either treatment, even when they were challenged repeatedly with an asthma trigger.

“Exacerbation frequency rather than asthma severity per se appears to be associated with a larger comorbidity burden and an increased risk of mortality, which reinforces the need to focus on ...

GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the Big Pharma’s push toward approval despite falling short on some ...

Depemokimab reduced the rate of exacerbations in patients with severe asthma with type 2 inflammation, according to phase 3 clinical trials.